Posted in | News | Copper | Mining Business

Mercator Subsidiary Initiates Sale Process to Divest El Pilar Copper Development Project

Stingray Copper Inc., a wholly-owned subsidiary of Mercator Minerals Ltd., announced today that it has initiated a sale process to divest of its El Pilar copper development project.

The El Pilar Project is an oxide copper development project located in Sonora, Mexico. All of the permits required to commence the construction have been received. A Feasibility Study was prepared for Mercator in accordance with National Instrument 43-101 on the El Pilar Project and was filed on October 18, 2012 on SEDAR at www.sedar.com under the Mercator company profile.

Stingray and its wholly-owned subsidiaries have negotiated a mutually acceptable forbearance arrangement with their creditor, RMB Australia Holdings Limited to allow Stingray to complete the Sale Process. In addition, Stingray and its wholly-owned subsidiaries have also negotiated a funding agreement with RMB that will allow them to continue normal course business at El Pilar during the Sale Process.

Stingray and its subsidiaries are not part of proceedings involving Mercator under the Bankruptcy and Insolvency Act (Canada).

It is the current intention of Stingray not to disclose developments with respect to the Sale Process until a specific transaction has been approved or otherwise determines that disclosure is necessary or appropriate. Stingray cautions that there are no assurances or guarantees that the Sale Process will result in a transaction or, if a transaction is undertaken, the terms or timing of such a transaction.

RBC Capital Markets has been engaged as financial advisor to conduct the Sale Process, and Deloitte Corporate Finance Inc. has been engaged as strategic advisor to Stingray.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.